alzheimer-s

Documents about alzheimer-s

• AV-1980R (Tau Vaccine) in Preclinical Alzheimer's Disease (TAURUS-1980)#184947ClinicalTrials.gov
• Bumetanide in Patients With Alzheimer's Disease#394657ClinicalTrials.gov
• Nasal Protollin in Early Symptomatic Alzheimer's Disease#390964ClinicalTrials.gov
• The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease#6831OpenAlex
• Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease#7394OpenAlex
• Systematic Multi-domain Alzheimer's Risk Reduction Trial#398239ClinicalTrials.gov
• Farming exposures and Alzheimer's disease: cross-sectional analysis within the French AGRICAN cohort#202472HAL (France)
• Analyzing single nuclei transcriptomes of Alzheimer's disease mice model#261747edoc-Server
• Dementia and Alzheimer's Disease: An Overview#167570Digital Commons @ University of Georgia School of Law
• Prazosin Treatment for Disruptive Agitation in Alzheimer's Disease#387271ClinicalTrials.gov
• Sociodemographic determinants of Alzheimer’s disease in primary care: evidence from the province of Salamanca (Spain)#283951Gestión del Repositorio Documental de la Universidad de Salamanca
• Clinical diagnosis of Alzheimer's disease#6815OpenAlex
• Studying the Effects of Antihypertensives on Individuals at Risk for Alzheimer's#158073ClinicalTrials.gov
• Phase I Clinical Study of AV-1959R: Abeta-targeting Anti-Alzheimer's Vaccine#287395ClinicalTrials.gov
• A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease (TRAILRUNNER-ALZ 1)#28528ClinicalTrials.gov
• No room of one’s own: Essays on caregiving and alzheimer's disease#234205Animo Repository
• 18-months Safety Follow-up Study of AADvac1, an Active Tau Vaccine for Alzheimer's Disease#28413ClinicalTrials.gov
• Tetrameric Transthyretin as a Protective Factor Against Alzheimer’s Disease#454624IRIS
• HAPPCAP-AD (Human-APPlication Combined Approach for Prevention of Alzheimer's Disease)#467509ClinicalTrials.gov
• Altered resting-state functional connectivity in individuals at risk for Alzheimer’s disease: a longitudinal study#329704Dipòsit Digital de la Universitat de Barcelona
• A distinct tau oligomer strain defines the molecular and proteomic landscape of rapidly progressive Alzheimer’s disease#398839HAL (France)
• Proteomic comparison of hippocampal neurofibrillary tangles in PART, intermediate Alzheimer's disease and advanced Alzheimer's disease.#425058NCBI PubMed Central
• Tau oligomerization induces nuclear lamina invagination and chromatin remodeling in Alzheimer's disease#127562Europe PMC
• Lifestyle factors and plasma biomarkers of Alzheimer's disease: A narrative review#179402HAL (France)
• The use of memantine for prevention of Alzheimer's disease: Pilot feasibility study rationale and protocol#217710Europe PMC
• The use of memantine for prevention of Alzheimer's disease: Pilot feasibility study rationale and protocol#231262Europe PMC
• PATIENT DERIVED-INDUCED PLURIPOTENT STEM CELL MODEL OF ALZHEIMER'S DISEASE REVEALS DYSREGULATED ANGIOGENESIS AND EARLY CELLULAR SENESCENCE IN HUMAN ENDOTHELIA#288521ScholarBank@NUS
• Cost-Effectiveness Analysis of Aducanumab Versus Placebo for Patients With Mild Cognitive Impairment and Mild Alzheimer’s Disease#450522Scholar Commons
• Four decades of Alzheimer's disease discoveries, data, and research resources: The NIH Alzheimer's Disease Research Center Program.#265496NCBI PubMed Central
• Methionine, Homocysteine, and Methylation Levels Predict Cognitive Decline in Alzheimer's Disease#266536Europe PMC
• White matter hyperintensities in Alzheimer's disease: Beyond vascular contribution#347655HAL (France)
• Diagnostic Performance of Plasma Biomarkers of Alzheimer's Disease Compared With CSF Markers#391041ClinicalTrials.gov
• NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease#7359OpenAlex
• Risk Reduction for Alzheimer's Disease#195454ClinicalTrials.gov
• Glial Cells in Behavioral and Psychological Symptoms of Alzheimer’s Disease#231276Europe PMC
• Intersection Of Capacity Law And Neurodegenerative Disease With A Focus On Alzheimer’s Medication#401534EliScholar
• Periodontitis and Alzheimer’s Disease: Is There a Connection?#453419Scholarly Commons
• Current potential biomarkers for Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis: review of literature#4659Europe PMC
• Amyloid‐related imaging abnormalities (ARIA) in anti‐amyloid therapies for Alzheimer's disease: An update from the Alzheimer's Association ARIA workgroup#125786Europe PMC
• Retinal Neurodegeneration in Type 2 Diabetes as Biomarker for Alzheimer´s Disease#175037ClinicalTrials.gov
• Bayesian modelling demonstrates clinically relevant heterogeneity in Tau PET patterns in Alzheimer's disease#235003Europe PMC
• Targeting proteostasis dysfunction in Alzheimer’s disease using small molecule modulators#459131Research Online
• Language as a central axis for studying Alzheimer's disease: From pathogenesis and clinical practice to scientific theory#475824Gestión del Repositorio Documental de la Universidad de Salamanca
• 2026 Alzheimer's disease facts and figures.#135628NCBI PubMed Central
• Norepinephrine and dopamine Imbalance in the medial frontal gyrus from patients with Alzheimer's disease#5380Europe PMC
• The role of ionotropic glutamate receptors in Alzheimer's disease: A scientometric analysis#5614Europe PMC
• Insight Into the Epigenetics of Alzheimer's Disease: A computational study from Human Interactome#31381Zenodo (CERN)
• Associations of plasma biomarkers with age in the presenilin-1 E280A autosomal dominant Alzheimer's disease kindred#259841Europe PMC
• The Cellular Mechanisms of Alzheimer's Disease Protection by the PILRA G78R Variant#321492BYU ScholarsArchive
• Does Following the MIND Diet Slow Cognitive Decline and Alzheimer’s Disease?#424421DigitalCommons@USU